{"filings":[{"id":1066276,"accession_number":"0001628280-26-043419","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K","filed_at":"2026-06-16T12:07:31+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sanuwave cuts Q2 2026 revenue guidance to $8.5-9.5M on Ultramist market disruption","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue guidance for Q2 2026 reduced to $8.5-$9.5M from prior guidance provided on May 13.","Downgrade driven by CMS reimbursement clawbacks causing wound care practice closures and cannibalization from used Ultramist systems.","Applicator consumables on pace for record quarterly unit volume in Q2.","CEO Morgan Frank sees positive applicator outlook but near-term headwinds from capital sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1059156,"accession_number":"0001628280-26-043306","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K","filed_at":"2026-06-15T21:27:28+00:00","items":["5.07"],"status":"ready","headline":"Sanuwave shareholders elect all five director nominees and ratify auditor at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Morgan Frank, Gregory Bazar, Jeffrey Blizard, Ian Miller, and James Tyler elected to board for 2026-2027 term.","Auditor Baker Tilly US, LLP ratified with 6,057,957 votes for, 45,261 against.","Advisory say-on-pay proposal approved with 4,666,444 votes for, 385,238 against.","Broker non-votes of 1,061,530 on director elections and say-on-pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":41362,"accession_number":"0001628280-26-034149","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K","filed_at":"2026-05-12T20:33:51+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sanuwave Q1 rev $9.6M (+3.1% YoY); net loss $1.4M; guides Q2 growth 10-15%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $9.6M, up 3.1% from $9.3M YoY; gross margin 77.3% vs 79.0%.","GAAP operating loss $1.1M, a $1.7M swing from $0.6M operating income YoY.","Ultramist consumables revenue $6.7M, up 15% YoY; set new all-time unit volume record.","Adjusted EBITDA $1.1M vs $2.3M YoY; net loss $1.4M, improved from $6.1M loss (prior year had $4.9M non-cash derivative loss).","Guides Q2 2026 revenue $11.1-11.6M (10-15% growth); reaffirms FY 2026 revenue $51-55M (16-25% growth)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":9619000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92730,"accession_number":"0001628280-26-025553","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sanuwave Health reports preliminary Q1 2026 revenue of $9.6-$9.7M, up 3-4% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue expected $9.6M-$9.7M, 3-4% increase vs Q1 2025, within prior guidance.","CEO notes several large deals slid out of Q1, impacting the lower end of guidance.","Wound care market facing reimbursement changes for skin substitutes, causing pause.","High interest at SAWC conference; CEO says they are leaning in, not pulling back.","Preliminary results subject to adjustment after completion of quarter-end close."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":9619000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103811,"accession_number":"0001628280-26-021464","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sanuwave records Q4 revenue $13.4M (+29.7% YoY); FY rev $44.1M; guides FY26 $51-55M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue record $13.4M (+29.7% YoY); FY 2025 revenue record $44.1M (+35% YoY).","GAAP operating income $2.0M Q4 ($4.9M FY); net income $7.7M Q4 vs loss $13.3M Q4 2024.","Adjusted EBITDA Q4 $4.8M vs $3.7M YoY; FY $13.6M vs $7.2M YoY.","Guides Q1 2026 rev $9.6-10.3M (+3-10%); FY 2026 rev $51-55M (+16-25% vs FY25).","Sold 255 UltraMist systems in Q4 (up from 135); consumables rev +10.6% to $6.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103810,"accession_number":"0001628280-26-017735","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["4.02"],"status":"ready","headline":"SANUWAVE Health restates prior financials due to sales tax liability of $4.9M-$5.2M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee determined non-reliance on quarterly and annual reports from March 2024 through September 2025.","Expected aggregate increase in liabilities of $4.9M to $5.2M as of Dec 31, 2025.","Expense increase of $1.6M-$1.8M for FY2024 and $1.7M-$1.9M for FY2025 including taxes, interest, penalties.","Company evaluating whether additional material weaknesses in internal control over financial reporting exist.","Restatement to be included in 2025 Form 10-K, which company expects to file timely."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103809,"accession_number":"0001628280-26-002203","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K/A","filed_at":"2026-01-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Sanuwave Health board adopts annual say-on-pay vote, next vote by 2031","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders voted for every-one-year frequency for advisory say-on-pay votes.","Board of Directors determined future advisory votes will be held annually.","Next stockholder vote on say-on-pay frequency must occur by the 2031 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120069,"accession_number":"0001628280-25-050406","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sanuwave Q3 record revenue $11.5M (+22% YoY); guides Q4 $13-14M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $11.5M, up 22% YoY and 13% sequentially; highest quarterly revenue in company history.","GAAP operating income $1.5M vs $2.0M YoY, impacted by $1.4M stock-based compensation (none in Q3 2024).","Net income $10.3M vs net loss of $20.7M YoY, driven by $6.1M non-cash derivative gain and $5.0M patent sale.","Adjusted EBITDA grew to $3.5M from $2.1M YoY.","Q4 2025 revenue guidance $13-14M; full-year FY2025 revenue guidance $44-45M (35-39% growth over FY2024)."],"consensus_eps_estimate":0.3244,"consensus_eps_actual":0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":30957000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120068,"accession_number":"0001628280-25-047577","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Former President Andrew Walko terminated without cause; receives $76,667 severance, continued option vesting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Andrew Walko, former President, terminated without cause effective Oct 24, 2025.","Severance: $76,666.67 cash (≈4 months +1 week salary) payable over 4 months; first installment Oct 31, 2025.","Stock options continue vesting during severance period; additional 8,889 options vest, total 44,444; exercise period extended.","Separation agreement includes release of claims, confidentiality, non-disparagement, and cooperation obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120067,"accession_number":"0001628280-25-043491","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K","filed_at":"2025-10-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sanuwave Health appoints Coyle COO, removes Stegagno; terminates President Walko","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Daniel Coyle appointed COO effective Sept 25, 2025; previously VP of Engineering.","Former COO Peter Stegagno removed, appointed Chief Regulatory Officer; no longer an executive officer.","President Andrew Walko terminated without cause effective Oct 24, 2025; no new President planned.","Coyle's base salary set at $225,000, bonus at 40% of salary, and options for 60,000 shares vesting quarterly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136650,"accession_number":"0001628280-25-042942","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["1.01","1.02","2.03","7.01","9.01"],"status":"ready","headline":"Sanuwave signs $28M J.P. Morgan credit facility, repays $27.5M NH Expansion debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$23M secured term loan (4-yr maturity) + $5M revolver backed by receivables, both at SOFR+350bp.","Total drawn at close ~$24M used to repay $27.5M NH Expansion facility; remaining $3.5M + $1.3M fees paid from cash.","No prepayment penalties; terms include max leverage 2.50x and min fixed charge coverage 1.25x.","Proceeds used for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136649,"accession_number":"0001628280-25-040975","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K","filed_at":"2025-08-21T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Sanuwave receives $5M cash from option exercise for patent sale","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Licensee exercised option on August 21, 2025, to acquire patents for intravascular shockwave applications.","Sanuwave received a $5.0M cash payment in connection with the option exercise.","Previously, the Licensee paid $2.5M for an exclusive license and the option in March 2024.","The patents are related to the field of intravascular shockwave applications.","No additional ongoing obligations from Sanuwave are disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136648,"accession_number":"0001628280-25-040914","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K","filed_at":"2025-08-20T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Sanuwave shareholders approve 500K share increase to equity plan at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All five director nominees elected: Morgan Frank, Gregory Bazar, Jeffrey Blizard, Ian Miller, James Tyler.","Baker Tilly US ratified as auditor for FY 2025 with 6,017,993 for, 1,473 against.","Equity plan amendment approved: 4,948,127 for, 202,867 against; increases authorized shares by 500,000 to 1,876,556.","Say-on-pay proposal passed with 5,136,449 for; frequency vote set at 1 year with 5,157,469 for.","Amendment was previously board-approved on June 6, 2025, subject to stockholder approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136647,"accession_number":"0001628280-25-039115","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sanuwave Q2 revenue $10.2M (+42% YoY), adjusted EBITDA $3.4M; guides Q3 $12-12.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 revenue $10.2M, +42% YoY from $7.2M; gross margin 78.3% vs 73.2%.","GAAP operating income $1.9M (incl $1.1M stock comp) vs $2.0M prior; adjusted EBITDA $3.4M vs $1.5M.","Sold 116 UltraMist systems in Q2 (vs 72 Q2 2024); consumables revenue $6.4M, +37% YoY.","Q3 2025 revenue guidance $12-12.7M; full-year 2025 reaffirmed $48-50M (47-53% growth).","CEO says full national sales coverage achieved mid-July, aiming for breakout performance in Q4 2025 and 2026."],"consensus_eps_estimate":-0.0887,"consensus_eps_actual":-0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":19506000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136646,"accession_number":"0001628280-25-037048","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Sanuwave Health enters separation agreement with former CCO Nanci Gilmore","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nanci Gilmore, former Chief Commercial Officer, was terminated without cause effective May 30, 2025.","Separation agreement provides lump sum cash of $97,916.70 (5 months salary) and pro-rated bonus of $14,790.81.","Stock options continue vesting through Jan 31, 2026: 31,111 options vest in three tranches (6,222; 6,223; 6,222).","Vested options remain exercisable at $14.20 per share until their original expiration dates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136645,"accession_number":"0001628280-25-034874","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K","filed_at":"2025-07-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SANUWAVE Health announces preliminary Q2 2025 revenue of $10.1-10.2M, up 41-42% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q2 2025 revenue $10.1-10.2M, increase 41-42% over Q2 2024.","First half 2025 revenue up 50-51% vs first half 2024.","Revenue within range of guidance provided in Q1 2025 earnings release.","CEO Morgan Frank notes sales team expanded to 13, covering all national territories for first time.","Full Q2 results expected on or around August 8, 2025."],"consensus_eps_estimate":-0.0887,"consensus_eps_actual":-0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":19506000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153849,"accession_number":"0001628280-25-033141","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"SANUWAVE Health sets 2025 annual meeting for Aug 19; deadline for proposals July 7","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual Meeting scheduled for August 19, 2025; record date July 8, 2025.","Stockholder proposals for inclusion in proxy materials due by July 7, 2025.","Advance notice for nominations or other proposals also due by July 7, 2025.","Company did not hold annual meeting in 2024, triggering earlier submission deadlines."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153848,"accession_number":"0001628280-25-029114","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Sanuwave terminates CCO Nanci Gilmore, appoints Dustin Libby as EVP of Commercial Operations","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nanci Gilmore terminated without cause as CCO on May 30, 2025; eligible for $97,916.67 severance (5 months salary) subject to release.","Dustin Libby appointed EVP of Commercial Operations effective June 3, 2025; brings 20 years of medical device experience.","Libby previously at Abiomed, where he helped scale a $15M surgical business to over $500M in revenue.","CEO Morgan Frank cited Libby's experience in scaling teams and systems for the next growth phase."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153847,"accession_number":"0001628280-25-028212","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K","filed_at":"2025-05-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"SANUWAVE Health appoints Gregory Bazar to board; A. Michael Stolarski resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["A. Michael Stolarski resigned from the Board effective May 27, 2025; no disagreement with the Company.","Gregory Bazar appointed to the Board and Compensation Committee, effective May 27, 2025.","Bazar received 41,333 stock options at an exercise price of $27.97, vesting quarterly over 12 installments.","Bazar will also receive quarterly grants of fully vested options worth $20,000 (Black-Scholes value)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153842,"accession_number":"0001628280-25-027118","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K/A","filed_at":"2025-05-21T23:59:59+00:00","items":["4.01"],"status":"ready","headline":"SANUWAVE finalizes engagement of Baker Tilly as new auditor for 2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Engagement letter signed May 20, 2025, after Baker Tilly completed client acceptance procedures.","Baker Tilly will begin audit work with review of June 30, 2025 quarterly financial statements.","No reportable events or disagreements with predecessor auditor CBIZ CPAs P.C."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153846,"accession_number":"0001628280-25-025878","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Sanuwave Health dismisses CBIZ CPAs, appoints Baker Tilly as auditor for FY2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CBIZ CPAs dismissed May 12, 2025, after only one month of engagement since April 11, 2025.","Baker Tilly US, LLP appointed as independent registered public accounting firm for the year ending Dec 31, 2025.","No accounting disagreements with CBIZ; previously disclosed material weaknesses in internal controls noted as reportable events.","Engagement of Baker Tilly effective with Q2 2025 review, subject to completion of client acceptance procedures; approved by Audit Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153845,"accession_number":"0001628280-25-024034","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sanuwave Q1 revenue $9.34M (+61% YoY); operating income $1.0M; Q2 guidance 40-50% growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $9.34M, up 61% from $5.79M in Q1 2024; gross margin 79.0% vs 72.6%; GAAP operating income $1.0M.","Adjusted EBITDA $2.3M vs -$59k in Q1 2024; net loss $5.7M driven by change in fair value of derivative liabilities.","UltraMist systems sold: 98 (128% increase from 43); consumables revenue +43% to $5.8M.","Q2 2025 revenue guidance $10.0-10.7M (40-50% YoY); full year 2025 guidance reaffirmed at $48-50M.","CEO highlights strong pipeline, comfortable inventory levels for larger customer engagements."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":9342000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153844,"accession_number":"0001628280-25-017706","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K","filed_at":"2025-04-14T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Sanuwave Health replaces auditor Marcum with CBIZ CPAs after business acquisition","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Marcum LLP resigned as auditor on April 10, 2025; CBIZ CPAs engaged on April 11, 2025 for FY 2025 audit.","CBIZ CPAs acquired Marcum's attest business effective Nov 1, 2024; audit services transition to CBIZ.","No disagreements or reportable events other than previously disclosed material weaknesses in internal controls.","Marcum's 2024 and 2023 audit reports included a going concern uncertainty about the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153843,"accession_number":"0001628280-25-017006","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K","filed_at":"2025-04-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SANUWAVE Health reports preliminary Q1 2025 revenue of $9.1M-$9.3M, up 57-61% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q1 2025 revenue $9.1M-$9.3M, highest Q1 in company history; +57-61% vs Q1 2024.","UltraMIST revenue up >65% YoY, constitutes ~99% of total revenues.","Results slightly above upper end of guidance given in Q4 2024 earnings release (March 21, 2025).","CEO Morgan Frank notes sales force restructuring complete; all manufacturing domestic, no significant tariff impact.","Full Q1 2025 results expected around May 9, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":9342000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172527,"accession_number":"0001628280-25-015674","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Sanuwave Health enters 5-year HQ lease in Eden Prairie; base rent $21,687/month","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease for 20,019 sq ft at 9600 W 76th St, Eden Prairie, MN, effective March 27, 2025.","Monthly base rent starts at $21,687.25, escalating 3.5% annually; rent commences by Sept 1, 2025.","Term is 60 months with one five-year renewal option at then-market rent.","Landlord provides up to $585,956 improvement allowance; tenant pays excess.","Lease is triple net; tenant pays proportionate share of property taxes and operating expenses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172526,"accession_number":"0001628280-25-014209","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K","filed_at":"2025-03-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SANUWAVE posts record Q4 revenue $10.3M, FY rev $32.6M; guides 47-53% growth in FY2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue $10.3M (+47% YoY); full year $32.6M (+60% YoY), both all-time records.","Gross margin improved to 77.9% (Q4) and 75.2% (FY); operating income $2.5M (Q4) and $5.4M (FY).","Adjusted EBITDA $3.7M in Q4 (vs $0.7M) and $7.2M for FY (vs -$1.2M), positive cash flow from operations.","Net loss $31.4M for FY driven by derivative liability fair value changes; capital structure simplified.","Guidance: Q1 2025 rev $8.4-9.0M (+45-55%); FY2025 rev $48-50M (+47-53%)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172525,"accession_number":"0001628280-25-011275","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K","filed_at":"2025-03-07T23:59:59+00:00","items":["5.03","5.05","7.01","8.01","9.01"],"status":"ready","headline":"Sanuwave Health receives Nasdaq approval; trading expected to start March 7 under SNWV","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Common stock approved for listing on Nasdaq Global Market; trading begins March 7, 2025.","Ticker 'SNWV' unchanged from OTCQB; no stockholder action required.","Board approved amended bylaws including exclusive forum, proxy rules, and director cap increase to 10.","New Code of Business Conduct and Ethics adopted effective March 4, 2025.","CEO Morgan Frank cites 'transition and progress' and expects uplisting to drive shareholder value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172524,"accession_number":"0001628280-25-001632","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K","filed_at":"2025-01-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"EVP of Sales Timothy Hendricks separates, receives $104K severance and option vesting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Timothy Hendricks separated as EVP of Sales effective January 3, 2025.","Severance: $104,116.67 (5 months base salary) plus $29,357.22 Q4 bonus paid.","Stock options continued vesting through May 31, 2025; 8,455 options to vest.","Hendricks signed a Separation and Release Agreement with confidentiality and non-disparagement clauses.","Cooperation in transition and legal matters required during the 5-month severance period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172523,"accession_number":"0001628280-25-001397","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sanuwave announces preliminary Q4 2024 revenue of $10.1-10.3M, record high, up 44-47% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue expected $10.1-10.3M, highest quarterly revenue in company history; increase of 44-47% YoY.","UltraMist revenue up >54% vs Q4 2023, representing ~98% of total Q4 revenue; applicator sales all-time record ~58% of total.","Full year 2024 preliminary revenue $32.4-32.6M, up 59-60% vs 2023.","CEO Morgan Frank cites third consecutive record quarter and 'breakout year' targeting rapid profitable growth.","Company expects to release complete Q4 and FY2024 results in March 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-7.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":32634000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172522,"accession_number":"0001628280-25-001163","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["5.02","7.01"],"status":"ready","headline":"Sanuwave Health appoints Timothy Wern as EVP Sales after Hendricks departure","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Timothy Hendricks separated as EVP of Sales effective January 3, 2025.","Timothy Wern appointed EVP of Sales effective January 6, 2025.","Wern has sales leadership experience at HeartWare, Abiomed, and Ceevra.","Separation agreement terms with Hendricks are still being negotiated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189519,"accession_number":"0001628280-24-047661","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Kevin Richardson resigns; 66,667 options fully vested and extended to 2034","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kevin A. Richardson II resigned as director effective November 12, 2024.","Company and Richardson entered mutual non-disparagement agreement and full settlement.","66,667 stock options granted Oct 22, 2024 are now fully vested.","Options remain exercisable until Oct 22, 2034 despite director resignation.","Options constitute full and final payment for all compensation and services."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189518,"accession_number":"0001628280-24-046481","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SANUWAVE Q3 revenue $9.4M (+89% YoY), operating income $2.0M; Q4 guidance 40-50% growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue record of $9.4M, up 89% vs Q3 2023; beat guidance of 65-75% increase.","UltraMist systems sold: 124 in Q3 2024 vs 55 in Q3 2023; consumables revenue $5.4M (+75%).","GAAP operating income $2.0M vs loss of $0.5M in Q3 2023; Adj. EBITDA $2.1M vs ($0.3M).","Net loss $20.7M (driven by derivative liability fair value change); year-to-date loss $18.6M.","Guides Q4 2024 revenue $9.7-10.5M (+40-50% YoY); FY2024 revenue >$32M; 1-for-375 reverse split Oct 18."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":22308000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.82,"calibrated_materiality_score":0.82,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189517,"accession_number":"0001628280-24-043824","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K","filed_at":"2024-10-25T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"SANUWAVE Health grants 365,334 stock options to four executives at $14.20","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Granted 160,000 options to Morgan Frank, 88,000 to Peter Sorensen, 50,667 to Tim Hendricks, 66,667 to Kevin Richardson.","Exercise price $14.20, equal to closing price on Oct 22, 2024 grant date.","Options vest quarterly over 3 years (12 equal installments) and expire after 10 years.","Grants made under the 2024 Equity Incentive Plan; no change in officer roles."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189516,"accession_number":"0001628280-24-043082","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K","filed_at":"2024-10-18T23:59:59+00:00","items":["1.01","3.02","3.03","5.03","7.01","9.01"],"status":"ready","headline":"Sanuwave completes 1-for-375 reverse split, $10.3M PIPE, and note exchange","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split 1-for-375 effective Oct 18; outstanding shares post-restructuring ~8.5M.","Exchanged $43.2M in convertible notes and associated warrants for ~4.0M post-split shares.","Closed $10.3M PIPE at $8.25/share led by AWM Investment, Manchester Management, Opaleye.","Entered consent/limited waiver with NH Expansion; repaid HealthTronics $1.4M note, regaining debt covenant compliance.","CEO Morgan Frank states transactions simplify cap table and position company for growth and profitability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206019,"accession_number":"0001140361-24-036929","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SANUWAVE Q2 revenue $7.2M (+53% YoY); guides Q3 growth 65-75%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $7.2M, up 53% YoY; 72 UltraMist systems sold vs 49 in Q2 2023.","GAAP operating income $2.0M; net income $6.6M vs loss $7.3M YoY.","Adjusted EBITDA $1.5M vs $171K YoY; year-to-date $1.4M vs -$1.6M.","Q3 2024 revenue guidance $8-8.5M (65-75% growth); gross margin mid 70s.","Reverse stock split approved, note/warrant exchange fully subscribed to simplify cap structure."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":12948000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206018,"accession_number":"0001140361-24-036620","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Shareholders approve reverse stock split (1:300-1:500) and 2024 Equity Plan with 516M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal 1: Reverse stock split authorized at ratio of 1-for-300 to 1-for-500, with final ratio set by Board.","Proposal 2: 2024 Equity Incentive Plan approved, authorizing up to 516,208,834 shares of common stock.","Both proposals passed with overwhelming stockholder support: ~96% for reverse split, ~96% for equity plan.","No further awards will be made under the prior 2006 Stock Incentive Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206017,"accession_number":"0001140361-24-033393","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K","filed_at":"2024-07-17T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Sanuwave gets forbearance extension on defaulted notes; $671K consent fee added to principal","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Existing defaults under NWPSA continue; lenders forbear remedies until Dec 31, 2024.","Consent fee of $670,841 added to principal of notes as of June 30, 2024.","Deferred interest of $163,519 and default interest of $272,532 for Q1 2024 recognized.","From Apr 1, 2024, deferred & default interest calculated on principal quarterly, including accrued default interest."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206016,"accession_number":"0001140361-24-032784","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K","filed_at":"2024-07-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sanuwave Health reports preliminary Q2 2024 revenue of $7.0-7.2M, highest quarterly revenue in history","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q2 2024 revenue $7.0M-$7.2M; up 50%-54% vs Q2 2023 and highest quarterly revenue ever.","UltraMist revenue grew >60% YoY and represents ~97% of total company revenue.","UltraMist applicator sales set all-time quarterly record, accounting for ~65% of total revenue.","Company expects to release full Q2 results in mid-August 2024; guidance at upper end of prior range."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":12948000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223034,"accession_number":"0001140361-24-031382","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K","filed_at":"2024-06-26T23:59:59+00:00","items":["1.02","7.01","9.01"],"status":"ready","headline":"Sanuwave terminates merger agreement with SEP Acquisition; pursues alternative capital plans","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated merger with SEP Acquisition Corp. on June 25, 2024; notice delivered that day.","Board unanimously determined termination was in best interest of stockholders.","Pursuing alternative capital structure improvements including reverse stock split and note/warrant exchange.","CEO cites improved options for growth, uplisting, and strengthening financial position."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223033,"accession_number":"0001140361-24-030816","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Sanuwave Health raises $1.8M: $1.3M convertible notes, $0.5M insider loan; warrants for 65M shares","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $1.3M convertible notes (15% interest, $0.04 conversion) and warrants for 65M shares ($0.067/$0.04 exercise).","Separate $0.5M promissory note to insider Manchester Explorer, 15% interest, matures Dec 18, 2024.","Total proceeds $1.8M; notes and warrants subordinated to NH Expansion Credit Fund.","Letter agreements allow Purchasers to exchange notes/warrants for common stock at $0.04 before SEPA merger or reverse split.","Waivers extended through Dec 31, 2024 for reverse split, share reserve, and registration obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223032,"accession_number":"0001140361-24-028711","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K","filed_at":"2024-06-04T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Sanuwave pays off $6.3M Celularity note for $2.075M, extends SEPA merger deadline to June 30","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Paid $2.075 million to settle and extinguish a $6.3 million note and interest owed to Celularity from the 2020 UltraMist acquisition.","Withdrew Nasdaq listing application due to bid price requirement; submitted application to Cboe BZX Exchange, currently under review.","Extended SEPA merger outside date to June 30, 2024; Sanuwave received unilateral right to terminate the merger agreement at any time.","Reaffirmed FY2024 revenue guidance above $30 million (50% growth) and Q2 2024 revenue growth of 45-55% versus Q2 2023.","Capital raise from longtime shareholders funded the debt settlement; company believes it is sufficiently funded for remainder of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223031,"accession_number":"0001140361-24-028567","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"SANUWAVE extends merger outside date with SEP Acquisition to June 30, 2024; gains unilateral termination right","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Outside Date under Merger Agreement extended from May 31, 2024 to June 30, 2024.","SANUWAVE granted unilateral right to terminate Merger Agreement at any time upon written notice.","This is the third amendment to the original August 23, 2023 merger agreement.","No other changes were made to the Merger Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223030,"accession_number":"0001140361-24-025326","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SANUWAVE Q1 revenue up 53% to $5.8M; operating loss narrows to $1.1M; reaffirms FY 2024 growth guidance of 50%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $5.8M (+53% YoY); gross margin 73% (+600bps); UltraMist consumables revenue $4.1M (+64%).","Operating loss $1.1M vs $2.0M in Q1 2023; net loss $4.5M includes $3.9M non-cash derivative charge.","Adjusted EBITDA loss improved to $59K from $1.8M loss YoY.","Guidance: Q2 2024 revenue growth 45-55% YoY; FY 2024 revenue growth of 50% reiterated.","Sold 43 UltraMist systems in Q1 (up from 28 in Q1 2023, down from 79 in Q4 2023)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":5786000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223029,"accession_number":"0001140361-24-022257","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K","filed_at":"2024-04-26T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Sanuwave and SEP Acquisition extend merger outside date to May 31, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Merger outside date extended from April 30, 2024 to May 31, 2024 via Amendment Number Two.","No other changes made to the Agreement and Plan of Merger dated August 23, 2023.","Closing condition requires SEPA to have at least $12.0M from un-redeemed stock and private placement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223028,"accession_number":"0001140361-24-019005","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K","filed_at":"2024-04-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SANUWAVE prelim Q1 revenue $5.7-5.9M, up 51-56% YoY, highest Q1 ever","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q1 2024 revenue $5.7M-$5.9M, up 51%-56% vs Q1 2023; highest Q1 in company history.","UltraMist revenue grew >55% YoY, accounting for ~95% of total revenue.","UltraMist applicator sales set all-time quarterly record, exceeding 65% of total revenue.","Full Q1 2024 results expected in mid-May; guidance reaffirmed."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":5786000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223027,"accession_number":"0001140361-24-017006","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"SANUWAVE fires CFO Toni Rinow without cause, hires Peter Sorensen as replacement","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Toni Rinow terminated without cause; receives $335,000 severance equal to one year's base salary.","Peter Sorensen, age 31, appointed CFO effective April 1, 2024; base salary of $225,000.","Sorensen previously VP of Finance & HR at Endogenex; also holds options for 105,000 shares.","Sorensen eligible for annual cash bonus up to 40% of base salary and three-month severance on termination.","New CFO has no family ties to executives or directors; no material interest in related transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242524,"accession_number":"0001140361-24-014708","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K","filed_at":"2024-03-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SANUWAVE reports record Q4 revenue $7.0M (+27% YoY), positive operating income, guides FY2024 50% growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 revenue record $7.0M (+27% vs Q4 2022 $5.5M); operating income $1.0M vs loss $1.5M.","FY2023 revenue $20.4M (+22% from $16.7M); adjusted EBITDA loss $1.2M vs $7.2M, improvement of $6.0M.","UltraMist systems: 211 sold in FY2023; Q4 consumables revenue $3.6M (+21% YoY).","Guidance: Q1 2024 revenue +45-55% vs Q1 2023; FY2024 revenue growth 50% vs FY2023.","Net income Q4 $18.2M (non-cash derivative fair value change); FY2023 net loss $25.8M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242523,"accession_number":"0001140361-24-011798","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K","filed_at":"2024-03-07T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Sanuwave Health licenses intravascular shockwave patents for $2.5M; extends debt forbearance to April 30, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Licensed intravascular shockwave patent portfolio to Vascular Wave LLC for $2.5M upfront; option to acquire for additional single-digit millions.","Noteholders consented to the license and waived related defaults; forbearance on existing defaults continued until April 30, 2024.","Patents released from NPA collateral; default rate interest continues to accrue during forbearance.","Company remains in default but avoids immediate enforcement; must still comply with all other obligations under NPA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242522,"accession_number":"0001140361-24-010145","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Sanuwave Health and SEP Acquisition Corp. extend merger outside date to April 30, 2024","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Amendment Number One dated Feb 27, 2024 extends merger outside date from Feb 28 to April 30, 2024.","Original Merger Agreement signed Aug 23, 2023; all other terms unchanged.","Closing requires SEPA to have at least $12.0 million from un-redeemed shares plus private placement.","Transaction is a SPAC merger; Sanuwave will become wholly-owned subsidiary of SEPA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242521,"accession_number":"0001140361-24-008781","cik":1417663,"company_name":"SANUWAVE Health, Inc.","ticker":"SNWV","form_type":"8-K","filed_at":"2024-02-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"SANUWAVE Health shareholders approve merger with SEP Acquisition Corp.","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Proposal 1 (merger agreement) approved with 798,379,869 For, 5,221,765 Against, 71,525 Abstain.","Proposal 2 (adjournment) also approved but not needed due to sufficient votes for Proposal 1.","Merger will result in SANUWAVE becoming a subsidiary of SEP Acquisition Corp.","Closing conditions include SEPA having at least $12.0M from non-redeemed shares and private placement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":142699988.85315758,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-02-21T23:59:59+00:00|242521"}